CureVac hit hard as its COVID jab fails to make the gradeCureVac has just had a harsh reminder of the perilous nature of drug development, after reporting that its Share XCureVac hit hard as its COVID jab fails to make the gradehttps://pharmaphorum.com/news/curevac-hit-hard-as-its-covid-jab-fails-to-make-the-grade/
Sage/Biogen’s zuranolone works in depression, but maybe not enoughSage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a Share XSage/Biogen’s zuranolone works in depression, but maybe not enoughhttps://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/
Regeneron drug saves lives in severe COVID-19, but it’s not for allPeople who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron’s Share XRegeneron drug saves lives in severe COVID-19, but it’s not for allhttps://pharmaphorum.com/news/regeneron-drug-saves-lives-in-severe-covid-19-but-its-not-for-all/
Biogen’s ambitions in gene therapy hit by another failed pivotal trialWhen Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that Share XBiogen’s ambitions in gene therapy hit by another failed pivotal trialhttps://pharmaphorum.com/news/biogens-ambitions-in-gene-therapy-are-hit-by-a-second-failed-phase-3-trial/
Novavax unveils phase 3 COVID jab data, but has it missed the boat in US?The top-line phase 3 data for Novavax’ COVID-19 vaccine look good, with a 90% overall efficacy rate, but Share XNovavax unveils phase 3 COVID jab data, but has it missed the boat in US?https://pharmaphorum.com/news/novavax-unveils-phase-3-covid-jab-data-but-has-it-missed-the-boat-in-us/
EHA21: Study raises BMS’ hopes for Reblozyl in less severe diseaseBristol-Myers Squibb has taken another step towards achieving its blockbuster hopes for beta thalassaemia-associated anaemia therapy Reblozyl, after Share XEHA21: Study raises BMS’ hopes for Reblozyl in less severe diseasehttps://pharmaphorum.com/news/eha21-study-raises-bms-hopes-for-reblozyl-in-less-severe-patients/
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHThe mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion’s infusion therapy Soliris, Share XEHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNHhttps://pharmaphorum.com/news/eha21-novartis-trumpets-iptacopan-as-oral-alternative-to-antibodies-in-pnh/
Lucid Group acquires US-based strategic brand consultants DiDLucid Group has acquired US strategic brand consultancy DiD to expand its presence in the US. Founded in Share XLucid Group acquires US-based strategic brand consultants DiDhttps://pharmaphorum.com/news/lucid-group-acquires-us-based-strategic-brand-consultants-did/
EHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionSanofi’s hopes of a speedy approval of first-in-class C1s inhibitor sutimlimab in rare disorder cold agglutinin disease (CAD) Share XEHA21: Sanofi builds case for rare disease drug sutimlimab after FDA rejectionhttps://pharmaphorum.com/news/eha21-sanofi-builds-case-for-rare-disease-drug-sutimlimab-after-fda-rejection/
90TEN expands senior leadership with new promotionsLondon-based healthcare communications consultancy 90TEN is expanding its senior leadership team with a new hire and two promotions. Share X90TEN expands senior leadership with new promotionshttps://pharmaphorum.com/r-d/news-r-d/90ten-claire-long-and-sabrina-gomersall-to-lead-communications/
Bayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinicBayer subsidiary BlueRock Therapeutics has dosed the first Parkinson’s disease patient in a phase 1 trial of its Share XBayer’s two-pronged cell/gene therapy assault on Parkinson’s enters clinichttps://pharmaphorum.com/news/bayers-two-pronged-cell-gene-therapy-assault-on-parkinsons-enters-clinic/
J&J backs out of $1.6bn blood cancer antibody alliance with ArgenxBelgian biotech Argenx has lost its development partner for acute myeloid leukaemia antibody cusatuzumab, after Johnson & Johnson Share XJ&J backs out of $1.6bn blood cancer antibody alliance with Argenxhttps://pharmaphorum.com/news/jj-backs-out-of-1-6bn-blood-cancer-antibody-alliance-with-argenx/
The Bloc hires Stuart Goldstein as COOStuart Goldstein has been hired as the chief operating officer at New-York-based healthcare creative agency The Bloc. In Share XThe Bloc hires Stuart Goldstein as COOhttps://pharmaphorum.com/news/the-bloc-hires-stuart-goldstein-as-coo/
MorphoSys offers $1.7bn for Constellation, but investors see starsShares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to Share XMorphoSys offers $1.7bn for Constellation, but investors see starshttps://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/
Amgen pays Kyowa $400m upfront for OX40 eczema drugAmgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim Share XAmgen pays Kyowa $400m upfront for OX40 eczema drughttps://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/
Sanofi’s venglustat bombs again, but isn’t dead yetShortly after failing a Parkinson’s disease study, Sanofi’s venglustat has missed the mark in another trial in autosomal Share XSanofi’s venglustat bombs again, but isn’t dead yethttps://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/
Novo Nordisk crowns cell therapy pipeline with $598m Heartseed dealNovo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed Share XNovo Nordisk crowns cell therapy pipeline with $598m Heartseed dealhttps://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/
Chasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciaConcert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia Share XChasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciahttps://pharmaphorum.com/news/chasing-lilly-concert-eyes-2023-filing-for-its-jak-drug-for-alopecia/
